Aeterna Zentaris to Present at the April 2020 Virtual Investor Summit
April 15 2020 - 8:15AM
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna
Zentaris” or the “Company”), a specialty biopharmaceutical company
commercializing and developing therapeutics and diagnostic tests,
today announced that Dr. Klaus Paulini, Chief Executive Officer of
Aeterna Zentaris will present at the April 2020 Virtual Investor
Summit on Thursday, April 23, 2020 at 10:00 AM ET.
A live audio webcast of the presentation will be
available on the Events and Presentations page of the Investors
section of the Company’s website (www.zentaris.com). Immediately
following the presentation, management will participate in an
interactive Q&A session with interested parties, allowing
participants to type in questions and receive live responses. A
webcast replay will be available two hours following the live
presentation and will be accessible for one year. To schedule a
one-on-one call with management, please contact the conference at
info@virtualinvestorsummit.com and for more information, please
visit virtualinvestorsummit.com. About Virtual Investor
Summit
The Virtual Investor Summit is an online
platform that offers both public and private companies, across
multiple industries the ability to stay active and engaged with the
investment community. Our inaugural summit on April 22-23, 2020
will feature company webcast presentations followed by a virtual,
interactive Q&A session, allowing participants to type in
questions and receive live responses. Interested participants also
have the ability to request one-on-one calls with a featured
company. For more information, please visit
virtualinvestorsummit.com.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty
biopharmaceutical company commercializing and developing
therapeutics and diagnostic tests. The Company’s lead product,
Macrilen™ (macimorelin), is the first and only U.S. FDA and
European Commission approved oral test indicated for the diagnosis
of adult growth hormone deficiency (AGHD). Macrilen™ is currently
marketed in the United States through a license agreement with Novo
Nordisk and Aeterna Zentaris receives double-digit royalties on
sales. Aeterna Zentaris owns all rights to macimorelin outside of
the U.S. and Canada.
Aeterna Zentaris is also leveraging the clinical
success and compelling safety profile of macimorelin to develop it
for the diagnosis of child-onset growth hormone deficiency (CGHD),
an area of significant unmet need.
The Company is actively pursuing business
development opportunities for the commercialization of macimorelin
in Europe and the rest of the world, in addition to other
non-strategic assets to monetize their value. For more information,
please visit www.zentaris.com and connect with the Company on
Twitter, LinkedIn and Facebook.
Forward Looking Statements
This press release contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 and Private Securities Litigation Reform Act, as
amended, including those relating to the Company's product
development, clinical and regulatory timelines, market opportunity,
competitive position, possible or assumed future results of
operations, business strategies, potential growth opportunities and
other statement that are predictive in nature. These
forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management's current beliefs and
assumptions.
These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
"expect," "anticipate," "intend," "plan," "believe," "estimate,"
"potential, "predict," "project," "should," "would" and similar
expressions and the negatives of those terms. These statements
relate to future events or our financial performance and involve
known and unknown risks, uncertainties, and other factors which may
cause actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company's filings with the
Securities and Exchange Commission. Prospective investors are
cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date of this press release.
The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Investor Contact:
Jenene Thomas JTC Team T (US): +1 (833) 475-8247 E:
aezs@jtcir.com
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Apr 2024 to May 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From May 2023 to May 2024